AstraZeneca secured ex‑China rights to Jacobio Pharmaceuticals’ pan‑KRAS inhibitor JAB‑23E73 in a deal worth up to $1.915 billion, paying $100 million up front. AstraZeneca will lead clinical development, regulatory submissions and commercialization outside China while the companies will co‑develop and commercialize in China under shared terms. In a related disclosure, AstraZeneca provided an additional $100 million to Jacobio to deepen its KRAS foothold, underscoring big pharma appetite for KRAS‑targeted small molecules after clinical advances in the field. The program gives AstraZeneca an early‑stage oral KRAS asset to broaden its oncology portfolio. For the oncology licensing market, the pact illustrates continued large‑scale out‑licensing from China to Western pharma and sustained strategic investment in KRAS biology.